Research progress on non-protein-targeted drugs for cancer therapy

Table 1 Approved RNA-based drugs in market at present

Class	Drug name	Target	Disease	Year of approval
ASO	Nusinersen	Exon 7 of SMN2	SMA	2016
	Eteplirsen	Exon 51 of DMD	DMD	2016
	Inotersen	TTR mRNA	FAP	2018
	Volanesorsen	ApoC3	FCS	2019
	Golodirsen	Exon 53 of DMD	DMD	2019
	Vitolarsen	Exon 53 of DMD	DMD	2020
	Casimersen	Exon 45 of DMD	DMD	2021
siRNA	Patisiran	TTR mRNA	FAP	2018
	Givosiran	ALAS1 mRNA	AHP	2020
	Lumasiran	HAO1 mRNA	PH1	2020
	Inclisiran	PCSK9	Hypercholesterolaemia	2020
mRNA	BNT162b2	Spike protein	SARA-CoV-2	2020
mRNA	mRNA-1273	Spike protein	SARA-CoV-2	2020

SMN2 survival pf motor neuron-2, SMA spinal muscular atrophy, TTR transthyretin, FAP familial amyloid polyneuropathy, ApoC3 apolipoprotein C3, FCS Familial chylomicronemia syndrome, DMD duchene muscular dystrophy, ALAS1 aminolevulinate synthase 1, AHP Acute hepatic porphyria, HAO1 Hydroxyacid oxidase 1, PH1 Primary hyperoxaluria type 1, PCSK9 proprotein convertase subtilisin/kexin 9, SARS-CoV-2 syndrome coronavirus 2

ISSN: 1756-9966